DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.

Trial Details

NCT ID

NCT07070440

Phase

PHASE1 / PHASE2

Sponsor

Dizal Pharmaceuticals

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

DZD6008
Pemetrexed
Carboplatin
Docetaxel

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Signed informed consent.
Age ≥18 years old.
Locally advanced or metastatic non-squamous non-small cell lung cancer by histopathology or cytology, not suitable for other radical treatment.
Documentation of EGFR sensitizing mutation confirmed by local laboratory.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →